Compare Quest Diagnostics Inc (DGX) vs Gigacloud Technology Inc (GCT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Gigacloud Technology Inc — how do they compare? Quest Diagnostics Inc trades at $237.63 (market cap $26.21B), while Gigacloud Technology Inc trades at $51.74 (market cap $1.84B). The key difference: Quest Diagnostics Inc is far larger — about 14.2× Gigacloud Technology Inc's market cap, and Quest Diagnostics Inc pays a 1.45% dividend while Gigacloud Technology Inc pays none. Which is the better fit depends on your goals.
| DGX | GCT | |
|---|---|---|
Market Cap | $26.21B | $1.84B |
Sector | Health | Technology |
52-Week High | $238.50 | $53.25 |
52-Week Low | $173.49 | $25.44 |
Enterprise Value | $31.97B | $1.97B |
Dividend Yield | 1.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.24, down 0.16% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $3.12 and raising its full-year outlook, driven by robust testing demand. Revenue grew to $11.04B in 2025, with net income of $992M, though margins face pressure from lower-margin deals and rising costs.
The outlook is positive due to raised guidance and AI integration enhancing efficiency, but risks include debt levels and margin compression. Analysts maintain a cautious buy stance with a $249.50 price target, indicating modest upside potential from current levels amid competitive and cost challenges.
GigaCloud Technology (GCT) trades at $51.68, up 0.06% on the day, with a bullish technical outlook supported by moving averages and strong support at $50. The company reported Q2 2026 EPS of $1.16, beating estimates, and maintains a net income margin of 10.65%. Revenue growth is projected to rise from $1.29B in 2025 to $1.5B in 2026, while analyst sentiment is positive with a 66.7% buy rating.
The stock presents a compelling opportunity due to consistent earnings beats, robust profitability metrics like a 32.34% ROE, and attractive valuation with a P/E of 12.25. Key risks include reliance on B2B furniture logistics, competitive pressures, and potential margin compression from higher costs. Institutional confidence is bolstered by a $120M buyback program announced in Q2 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Gigacloud Technology Inc
Gigacloud Technology operates a global B2B e-commerce marketplace for large-parcel goods. It provides a comprehensive solution for furniture manufacturers and retailers with integrated logistics and fulfillment.
Read more on GCT →
